Optimizing the dosing regimens for intravascular administrations of oncolytic adenovirus

被引:0
|
作者
Tsai, V [1 ]
Johnson, DE [1 ]
Schluep, T [1 ]
Quijano, E [1 ]
Wen, SF [1 ]
Ralston, R [1 ]
Demers, GW [1 ]
Ramachandra, M [1 ]
机构
[1] Canji Inc, San Diego, CA USA
来源
IMMUNOLOGY 2004: GENOMIC ISSUES, IMMUNE SYSTEM ACTIVATION AND ALLERGY | 2004年
关键词
D O I
暂无
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The objective of this study was to determine the impact of multiple-dose regimens on the activity of the final dose of an oncolytic adenovirus. Groups of tumor-bearing mice were dosed with the oncolytic adenovirus 01/PEME on each of 1, 2, 3, or 4 consecutive days prior to final treatment with a single dose of a different oncolytic adenovirus carrying the reporter gene, dl01/07-luc. Delivery and replication of the dl01/07-luc in the tumor and liver were determined by quantifying virus DNA copies by PCR and reporter gene activity by a luciferase enzymatic assay. Our results showed that there was a regimen-dependent effect after multiple prior intravenous administrations on the biological activity of dl01/07-luc.
引用
收藏
页码:429 / 436
页数:8
相关论文
共 50 条
  • [31] Oncolytic adenovirus for treatment of malignant ascites
    Hemminki, Akseli
    Heinio, Camilla
    MOLECULAR THERAPY-ONCOLYTICS, 2022, 26 : 302 - 303
  • [32] Evolution of oncolytic adenovirus for cancer treatment
    Choi, Joung-Woo
    Lee, Jung-Sun
    Kim, Sung Wan
    Yun, Chae-Ok
    ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (08) : 720 - 729
  • [33] Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
    Zhao, Yaqi
    Liu, Zheming
    Li, Lan
    Wu, Jie
    Zhang, Huibo
    Zhang, Haohan
    Lei, Tianyu
    Xu, Bin
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [34] Oncolytic adenovirus: Getting there is half the battle
    Ross, PJ
    Parks, RJ
    MOLECULAR THERAPY, 2003, 8 (05) : 705 - 706
  • [35] Oncolytic adenovirus effective in patients with glioblastoma
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2018, 15 : 266 - 266
  • [36] Oncolytic adenovirus based on serotype 3
    O Hemminki
    G Bauerschmitz
    S Hemmi
    S Lavilla-Alonso
    I Diaconu
    K Guse
    A Koski
    R A Desmond
    M Lappalainen
    A Kanerva
    V Cerullo
    S Pesonen
    A Hemminki
    Cancer Gene Therapy, 2011, 18 : 288 - 296
  • [37] IMMUNE ONCOLYTIC ADENOVIRUS FOR DIPG TRFATMENT
    Laspidea, Virginia
    Varela-Guruceaga, Maider
    Garcia-Moure, Marc
    Gonzalez-Huarriz, Marisol
    Fueyo, Juan
    Gomez-Manzano, Candelaria
    Alonso, Marta M.
    NEURO-ONCOLOGY, 2019, 21 : 119 - 119
  • [38] Increasing the Efficacy of Oncolytic Adenovirus Vectors
    Toth, Karoly
    Wold, William S. M.
    VIRUSES-BASEL, 2010, 2 (09): : 1844 - 1866
  • [39] Prostate Targeted TSTA Oncolytic Adenovirus
    Sato, Makoto
    Huyn, Steve
    Powell, Russell
    Carey, Michael
    Gambhir, Sanjiv S.
    Wu, Lily
    MOLECULAR THERAPY, 2006, 13 : S117 - S118
  • [40] Designer Oncolytic Adenovirus: Coming of Age
    Baker, Alexander T.
    Aguirre-Hernandez, Carmen
    Hallden, Gunnel
    Parker, Alan L.
    CANCERS, 2018, 10 (06)